BACKGROUND: Data on the prevalence of the complications of antiretroviral therapy (ART) (diabetes, central fat accumulation, peripheral fat wasting, and dyslipidemia) in sub-Saharan Africa are sparse. We examined the prevalence and associated risk factors of dysglycemia and insulin sensitivity in HIV-infected South Africans. METHODS: HIV-infected patients, on nonnucleoside reverse transcriptase inhibitor-based ART or ART-naive, had oral glucose tolerance tests and clinical anthropometry. Insulin sensitivity and β-cell function were assessed. RESULTS: The prevalence of dysglycemia in 406 ART-naive patients and 443 patients on ART was 25.7% and 21.9% (P = 0.193), respectively. Dysglycemic patients on ART had a similar body mass index (P = 0.440), greater waist circumference (P = 0.047), and smaller calf skinfold thickness (P = 0.015) than dysglycemic ART-naive patients but no difference in β-cell function or insulin sensitivity. Normoglycemic patients on ART had a greater body mass index (P = 0.0009), waist circumference (P = 0.0001), and abdominal skinfold thickness (P = 0.040), similar calf skinfold thickness (P = 0.079), and reduced β-cell function [lower insulinogenic index (P = 0.027) and oral disposition index (D(o), P = 0.020)] compared with normoglycemic ART-naive patients. In multivariate analysis, older age [odds ratio (OR): 1.04, 95% confidence interval (CI): 1.02 to 1.06], male gender (OR: 1.96, 95% CI: 1.28 to 2.99), higher CD4 count (OR: 1.0, 95% CI: 1.00 to 1.02) and use of efavirenz (OR: 1.70, 95% CI: 1.19 to 2.45) were associated with dysglycemia. CONCLUSIONS: The prevalence of dysglycemia in ART-naive and ART patients was similar. Peripheral fat wasting was more common in dysglycemic patients on ART. The association of efavirenz with dysglycemia is important because first-line ART regimens in the developing world include nonnucleoside reverse transcriptase inhibitors, and increasingly, efavirenz is selected because of its perceived lower toxicity than nevirapine.
BACKGROUND: Data on the prevalence of the complications of antiretroviral therapy (ART) (diabetes, central fat accumulation, peripheral fat wasting, and dyslipidemia) in sub-Saharan Africa are sparse. We examined the prevalence and associated risk factors of dysglycemia and insulin sensitivity in HIV-infected South Africans. METHODS:HIV-infectedpatients, on nonnucleoside reverse transcriptase inhibitor-based ART or ART-naive, had oral glucose tolerance tests and clinical anthropometry. Insulin sensitivity and β-cell function were assessed. RESULTS: The prevalence of dysglycemia in 406 ART-naive patients and 443 patients on ART was 25.7% and 21.9% (P = 0.193), respectively. Dysglycemic patients on ART had a similar body mass index (P = 0.440), greater waist circumference (P = 0.047), and smaller calf skinfold thickness (P = 0.015) than dysglycemic ART-naive patients but no difference in β-cell function or insulin sensitivity. Normoglycemic patients on ART had a greater body mass index (P = 0.0009), waist circumference (P = 0.0001), and abdominal skinfold thickness (P = 0.040), similar calf skinfold thickness (P = 0.079), and reduced β-cell function [lower insulinogenic index (P = 0.027) and oral disposition index (D(o), P = 0.020)] compared with normoglycemic ART-naive patients. In multivariate analysis, older age [odds ratio (OR): 1.04, 95% confidence interval (CI): 1.02 to 1.06], male gender (OR: 1.96, 95% CI: 1.28 to 2.99), higher CD4 count (OR: 1.0, 95% CI: 1.00 to 1.02) and use of efavirenz (OR: 1.70, 95% CI: 1.19 to 2.45) were associated with dysglycemia. CONCLUSIONS: The prevalence of dysglycemia in ART-naive and ART patients was similar. Peripheral fat wasting was more common in dysglycemic patients on ART. The association of efavirenz with dysglycemia is important because first-line ART regimens in the developing world include nonnucleoside reverse transcriptase inhibitors, and increasingly, efavirenz is selected because of its perceived lower toxicity than nevirapine.
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Kristine Mace Erlandson; Douglas Kitch; Camlin Tierney; Paul E Sax; Eric S Daar; Kathleen M Melbourne; Belinda Ha; Grace A McComsey Journal: AIDS Date: 2014-06-19 Impact factor: 4.177
Authors: Julie A Ake; Christina S Polyak; Trevor A Crowell; Francis Kiweewa; Michael Semwogerere; Lucas Maganga; Emmanuel Bahemana; Jonah Maswai; Rither Langat; John Owuoth; Solomon Otieno; Babajide Keshinro; Allahna L Esber; Michelle Liu; Leigh Anne Eller; Kavitha Ganesan; Ajay P Parikh; Tiffany E Hamm; Merlin L Robb; Patrick W Hickey; Victor G Valcour; Nelson L Michael Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: D Moyo; G Tanthuma; M S Cary; O Mushisha; G Kwadiba; F Chikuse; A P Steenhoff; M J A Reid Journal: Diabetes Res Clin Pract Date: 2014-01-15 Impact factor: 5.602
Authors: Phumla Z Sinxadi; Joel A Dave; David C Samuels; Jeannine M Heckmann; Gary Maartens; Naomi S Levitt; C William Wester; David W Haas; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2013-03-15 Impact factor: 2.205
Authors: Stephen M Ford; Liz Simon; Curtis Vande Stouwe; Tim Allerton; Donald E Mercante; Lauri O Byerley; Jason P Dufour; Gregory J Bagby; Steve Nelson; Patricia E Molina Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-09-07 Impact factor: 3.619
Authors: Ditte Steiniche; Sanne Jespersen; Christian Erikstrup; Henrik Krarup; Aase Handberg; Lars Østergaard; Thorny Haraldsdottir; Candida Medina; Faustino Gomes Correira; Alex Lund Laursen; Morten Bjerregaard-Andersen; Christian Wejse; Bo Langhoff Hønge Journal: Trans R Soc Trop Med Hyg Date: 2016-04 Impact factor: 2.184